Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04558775 · ClinicalTrials.gov registry record
TEWL Biomarker Study for Diabetic Foot Ulcer Recurrence
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 418
- Enrollment target
NCT04558775: Completed study, sponsored by University of Michigan.
NCT04558775 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 418 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04558775 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 418 participants
- Enrollment target
Study Summary
This is a multicenter study of patients with diabetic foot ulcers (DFU) to develop and validate potential tissue-based biomarkers that predict DFU wound recurrence. Trans-epidermal water loss (TEWL) will be measured on the closed wound site and a location similar to the wound site (reference site). Participants will be enrolled within two weeks after closure of their DFU. Complete wound healing will be verified at a second visit two weeks later and this visit will start the 16 week timeline where participants will be followed weekly by phone until the earliest of DFU wound recurrence or 16 weeks. Participants who experience a DFU wound recurrence and a subset of participants who do not experience a DFU wound recurrence by week 16 will be asked to attend one final visit.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2022-12-30 |
What the finished NCT04558775 record still lists
NCT04558775 is an observational study that tracks outcomes without assigning an intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT04558775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04558775 about?
NCT04558775 is a clinical study titled "TEWL Biomarker Study for Diabetic Foot Ulcer Recurrence". This is a multicenter study of patients with diabetic foot ulcers (DFU) to develop and validate potential tissue-based biomarkers that predict DFU wound recurrence. Trans-epidermal water loss (TEWL) will be measured on the closed wound site and a location similar to the wound site (reference site). ...
What is the current status of trial NCT04558775?
This trial is currently completed. The enrollment target is 418 participants. The study started on 2020-06-17. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT04558775?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT04558775?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI